Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sulindac Placebo Clear all
Completed Not applicable Interventional Results available

A Randomized Study of Sulindac in Oral Premalignant Lesions

NCT00299195
View directory record Official record
Conditions
Leukoplakia, Oral, Benign Neoplasms
Interventions
sulindac, Placebo
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Sep 3, 2026, 1:12 AM EDT
Active, not recruiting Phase 2 Interventional

The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)

NCT04207944
View directory record Official record
Conditions
IPMN, IPMN, Pancreatic
Interventions
Sulindac 400 MG, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
21 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 3, 2026, 1:12 AM EDT
Terminated Phase 2 Interventional

Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer

NCT00062023
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Acetylsalicylic acid (Aspirin), Sulindac, Ursodiol, Sulindac Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
40 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Sep 3, 2026, 1:12 AM EDT
Active, not recruiting Phase 3 Interventional

S0820, Adenoma and Second Primary Prevention Trial

NCT01349881
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2032
U.S. locations
990
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 617 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 3, 2026, 1:12 AM EDT
Completed Phase 3 Interventional Results available

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

NCT01483144
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Eflornithine, Eflornithine Placebo, Sulindac 150 MG, Sulindac placebo
Drug
Lead sponsor
Cancer Prevention Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
10
States / cities
La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 3, 2026, 1:12 AM EDT
Withdrawn Phase 2 Interventional

Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40

NCT04823052
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Sulindac (HLX-0201), dose strength 1, Sulindac (HLX-0201), dose strength 2, Placebo, Gaboxadol (HLX-0206)
Drug
Lead sponsor
Healx Limited
Industry
Eligibility
13 Years to 40 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Aurora, Colorado • Miami, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Sep 3, 2026, 1:12 AM EDT
Completed Phase 2 Interventional Results available

Sulindac and Breast Density in Women at Risk of Developing Breast Cancer

NCT04542135
View directory record Official record
Conditions
Breast Cancer
Interventions
Sulindac Pill, Placebo
Drug
Lead sponsor
Alison Stopeck
Other
Eligibility
35 Years to 70 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 3, 2026, 1:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma

NCT00841204
View directory record Official record
Conditions
Precancerous Condition
Interventions
sulindac, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Tucson, Arizona • Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced Sep 3, 2026, 1:12 AM EDT
Completed Phase 3 Interventional Results available

Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps

NCT00118365
View directory record Official record
Conditions
Precancerous Condition
Interventions
placebo, eflornithine, sulindac, laboratory biomarker analysis
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Sep 3, 2026, 1:12 AM EDT
Completed Phase 1 Interventional

Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT01515137
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Erlotinib, Erlotinib plus sulindac, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Sep 3, 2026, 1:12 AM EDT
Completed Phase 2 Interventional Results available

Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

NCT00368927
View directory record Official record
Conditions
Precancerous Condition, Stage I Non-small Cell Lung Cancer, Tobacco Use Disorder
Interventions
sulindac, placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
5
States / cities
Scottsdale, Arizona • Tampa, Florida • Burlington, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Sep 3, 2026, 1:12 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients

NCT01187901
View directory record Official record
Conditions
Adenomatous Polyposis Coli
Interventions
Erlotinib, Sulindac, Placebo A, Placebo B
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 69 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Sep 3, 2026, 1:12 AM EDT
Completed Phase 2 Interventional Results available

Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia

NCT00335504
View directory record Official record
Conditions
Colon Cancer, Precancerous Condition, Rectal Cancer
Interventions
oligofructose-enriched inulin, sulindac, placebo, atorvastatin calcium, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Sep 3, 2026, 1:12 AM EDT
Completed Phase 2 Interventional

Exisulind Versus Placebo After Surgical Removal of the Prostate

NCT00166426
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Exisulind
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 15, 2009 · Synced Sep 3, 2026, 1:12 AM EDT
Terminated Phase 2 Interventional Results available

Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer

NCT01856322
View directory record Official record
Conditions
Colorectal Cancer, Liver Metastasis, Colorectal Adenocarcinoma
Interventions
Sulindac, Placebo, Validate assays and shipping methods
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Sep 3, 2026, 1:12 AM EDT
Completed Phase 3 Interventional

A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients

NCT00085826
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Exisulind
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
114
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2011 · Synced Sep 3, 2026, 1:12 AM EDT